Loading…
Based on limited metadata, the FDA issued a Warning Letter to Lopez Gonzalez Santana Corporation (operating as Domel and Dermixx) on July 16, 2018, regarding products classified as "Other." Without access to the full letter text or subject line details, the specific nature of the regulatory violations cannot be determined from the available information. The issuing office is not specified in the metadata, limiting clarity on which FDA division initiated the warning. To understand the complete scope and details of the violations, the full Warning Letter text would need to be reviewed.